



## SEQUENCE LISTING

<110> DAWSON, GLYN  
SEUNGUEN, JULIA CHO

<120> COMPOUNDS THAT ENHANCE TUMOR DEATH

<130> ARCD:351US

<140> 09/930,559

<141> 2001-08-15

<150> 60/225,526

<151> 2000-08-15

<160> 11

<170> PatentIn Ver. 2.1

<210> 1

<211> 2279

<212> DNA

<213> Human

<400> 1

```
ggcacgagcg aagatggcgt cgcccggtcg cctgtggctc ttggctgtgg ctctcctgcc 60
atggacctgc gcttctcggg cgtgcagca tctggaccgc cggcgccgc tgccgttggt 120
gatctggcat gggatgggag acagctgttg caatccctta agcatgggtg ctattaaaaa 180
aatggtggag aagaaaatac ctggaattta cgtcttatct ttagagattg ggaagacct 240
gatggaggac gtggagaaca gcttcttctt gaatgtcaat tcccaagtaa caacagtgtg 300
tcaggcactt gctaaggatc cttaaattgca gcaaggctac aatgctatgg gattctccca 360
gggaggccaa tttctgaggg cagtggctca gagatgccct tcacctcca tgatcaatct 420
gatctcggtt gggggacaac atcaagggtg ttttggaact cctcgatgcc caggagagag 480
ctctcacatc tgtgacttca tccgaaaaac actgaatgct ggggcgtact ccaaagttgt 540
tcaggaacgc ctctgtcaag ccgaatactg gcatgacccc ataaaggagg atgtgtatcg 600
caaccacagc atcttcttgg cagatataaa tcaggagcgg ggtatcaatg agtcctacaa 660
gaaaaacctg atggccctga agaagtttgt gatggtgaaa ttcttcaatg attccattgt 720
ggacctgtga gattcggagt ggtttggatt ttacagaagt ggccaagcca aggaaacat 780
tcccttacag gagacctccc tgtacacaca ggaccgcctg gggctaaagg aaatggacaa 840
tgcaggacag ctagtgtttc tggctacaga aggggacct cttcagttgt ctgaagaatg 900
gttttatgcc cacatcatac cattccttgg atgaaaccgc tatagttcac aatagagctc 960
agggagcccc taactcttcc aaaccacatg ggagacagtt tccttcatgc ccaagcctga 1020
gctcagatcc agcttgcaac taatccttct atcatctaac atgcactact tggaaagatc 1080
taagatctga atcttatcct ttgccatctt ctgttaccat atggtgttga atgcaagttt 1140
aattaccatg gagattgttt tacaaacttt tgatgtggtc aagttcagtt ttagaaaagg 1200
gagtctgttc cagatcaggg ccagaactgt gccaggccc aaaggagaca actaactaaa 1260
gtagtgagat agattctaag ggcaaacatt tttccaagtc ttgccatatt tcaagcaaag 1320
aggtgcccag gcctgaggta ctcacataaa tgctttgttt tgctggtgat ttaaccagtg 1380
```

cttggaaaaa tcttgcttgg ctatttctgc atcatttctt aaggctgcct tcctctctga 1440  
 gtacgttgcc ctctgtgcta tcaatcatct tatcatcaat tattagacaa atcccactgg 1500  
 cctacagtct tgcttctgca gcacccactt tgtctcctca ggtagtgatg aattagttgc 1560  
 tgtcacaaaa ggagggaagt agcacccaaa ttaaattgct taagagagga aatgtacatc 1620  
 ttgtataact tagggagcga agaaaatgta ggcgcgaaaag tgaaaagtga ggcagctagt 1680  
 tcttctctatt ccattctcga ccaacctgcc ctttcttaat atgactagtg gtcttgatgc 1740  
 tagagtcaac ttactctggt gctggcttta gcagagaata ggaggaacca tatgaaaaag 1800  
 atcaggcttt ctgacttcca tccccaaaac acatttacca gcatactcca aactgtttct 1860  
 gatgtgttcc atgagaaaag gattgtttgc tcaaaaagct tggaaaatac tacacactcc 1920  
 ctttctcctt ctggagatca acccacatta gagtgtctaa ggactcctga gaattcctgt 1980  
 tacagtaaac aaaactaacg taatctacca tttcctacac tatttgagca tggaaatcat 2040  
 agtccccact ctatgaaaac ttaacgcttt ttggaagaca tttctgtagc atgtcagttt 2100  
 ggagaaatga tgagctacgc cttgatgaaa gaaccgtggt ggtgctgcta agtttagcca 2160  
 ttatgggtttt tcctttctct ctcttaagcc ttattcttca actaaaagat gaggattaag 2220  
 agcaagaagt tgggggggat gtgaaaataa ttttatgagg ttgtctaaaa tctcgtgcc 2279

<210> 2

<211> 306

<212> PRT

<213> Human

<400> 2

Met Ala Ser Pro Gly Cys Leu Trp Leu Leu Ala Val Ala Leu Leu Pro  
 1 5 10 15

Trp Thr Cys Ala Ser Arg Ala Leu Gln His Leu Asp Pro Pro Ala Pro  
 20 25 30

Leu Pro Leu Val Ile Trp His Gly Met Gly Asp Ser Cys Cys Asn Pro  
 35 40 45

Leu Ser Met Gly Ala Ile Lys Lys Met Val Glu Lys Lys Ile Pro Gly  
 50 55 60

Ile Tyr Val Leu Ser Leu Glu Ile Gly Lys Thr Leu Met Glu Asp Val  
 65 70 75 80

Glu Asn Ser Phe Phe Leu Asn Val Asn Ser Gln Val Thr Thr Val Cys  
 85 90 95

Gln Ala Leu Ala Lys Asp Pro Lys Leu Gln Gln Gly Tyr Asn Ala Met  
 100 105 110

Gly Phe Ser Gln Gly Gly Gln Phe Leu Arg Ala Val Ala Gln Arg Cys  
 115 120 125

Pro Ser Pro Pro Met Ile Asn Leu Ile Ser Val Gly Gly Gln His Gln

130	135	140	
Gly Val Phe Gly Leu Pro Arg Cys Pro Gly Glu Ser Ser His Ile Cys			
145	150	155	160
Asp Phe Ile Arg Lys Thr Leu Asn Ala Gly Ala Tyr Ser Lys Val Val			
	165	170	175
Gln Glu Arg Leu Val Gln Ala Glu Tyr Trp His Asp Pro Ile Lys Glu			
	180	185	190
Asp Val Tyr Arg Asn His Ser Ile Phe Leu Ala Asp Ile Asn Gln Glu			
	195	200	205
Arg Gly Ile Asn Glu Ser Tyr Lys Lys Asn Leu Met Ala Leu Lys Lys			
	210	215	220
Phe Val Met Val Lys Phe Leu Asn Asp Ser Ile Val Asp Pro Val Asp			
225	230	235	240
Ser Glu Trp Phe Gly Phe Tyr Arg Ser Gly Gln Ala Lys Glu Thr Ile			
	245	250	255
Pro Leu Gln Glu Thr Ser Leu Tyr Thr Gln Asp Arg Leu Gly Leu Lys			
	260	265	270
Glu Met Asp Asn Ala Gly Gln Leu Val Phe Leu Ala Thr Glu Gly Asp			
	275	280	285
His Leu Gln Leu Ser Glu Glu Trp Phe Tyr Ala His Ile Ile Pro Phe			
	290	295	300
Leu Gly			
305			

<210> 3  
 <211> 7  
 <212> PRT  
 <213> Human

<400> 3  
 Gly Cys Val Lys Ile Lys Lys  
 1 5

<210> 4  
 <211> 8

<212> PRT  
<213> Human

<400> 4

Ile Arg Tyr Cys Trp Leu Arg Arg  
1 5

<210> 5

<211> 9

<212> PRT

<213> Human

<400> 5

Val Thr Thr Leu Cys Cys Gly Lys Asn  
1 5

<210> 6

<211> 7

<212> PRT

<213> Human

<400> 6

Met Leu Cys Cys Met Arg Arg  
1 5

<210> 7

<211> 8

<212> PRT

<213> Human

<400> 7

Met Gly Cys Leu Gly Asn Ser Lys  
1 5

<210> 8

<211> 8

<212> PRT

<213> Human

<400> 8

Met Gly Cys Leu Gly Asn Ser Lys  
1 5

<210> 9  
<211> 10  
<212> PRT  
<213> Human

<400> 9  
Gly Cys Met Ser Cys Lys Cys Val Leu Ser  
1 5 10

<210> 10  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 10  
tctaggtacc aagatggcgt cgcccggctg cctgt 35

<210> 11  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 11  
acggtctaga tcatccaagg aatggatatga tgtgggca 38